Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study

1Polycythemia vera: The natural history of 1213 patients followed for 20 years. Gruppo italiano studio policitemia. Ann Intern Med. 1995; 123(9): 656-664.Polycythemia vera: The natural history of 1213 patients followed for 20 years. Gruppo italiano studio policitemia Ann Intern Med. 1995 123 9 656 664Search in Google Scholar

2Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990; 8(3): 556-562.CortelazzoSVieroPFinazziGD’EmilioARodeghieroFBarbuiT. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia J Clin Oncol. 1990 8 3 556 562Search in Google Scholar

3Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Glglielmelli P, Antonioli E, et al.Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood. 2010; 115(4): 778-782.BarbuiTCarobbioACervantesFVannucchiAMGlglielmelliPAntonioliE Thrombosis in primary myelofibrosis: Incidence and risk factorsn Blood. 2010 115 4 778 782Search in Google Scholar

4Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004; 117(10): 755-761.PassamontiFRumiEPungolinoEMalabarbaLBertazzoniPValentiniM Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med. 2004 117 10 755 761Search in Google Scholar

5Watson KV, Key N. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors. Br J Haematol. 1993; 83(2): 198-203.WatsonKVKeyN. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors Br J Haematol. 1993 83 2 198 203Search in Google Scholar

6Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin. Oncol. 2011; 29(23): 3179-3184.BarbuiTThieleJPassamontiFRumiEBoveriERuggeriM Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study J Clin. Oncol. 2011 29 23 3179 3184Search in Google Scholar

7Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, et al. High rate of abnormal blood values and vascular complications before diagnosis of myelopro-liferative neoplasms. Eur J Intern Med. 2015; 26(5): 344-347.EnblomALindskogEHasselbalchHHersbyDBakMTetuJ High rate of abnormal blood values and vascular complications before diagnosis of myelopro-liferative neoplasms Eur J Intern Med. 2015 26 5 344 347Search in Google Scholar

8Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of cal-reticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25): 2379-2390.KlampflTGisslingerHHarutyunyanASNivarthiHRumiEMilosevicJD Somatic mutations of cal-reticulin in myeloproliferative neoplasms N Engl J Med. 2013 369 25 2379 2390Search in Google Scholar

9Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25): 2391-2405.NangaliaJMassieCEBaxterEJNiceFLGundemGWedgeDC Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N Engl J Med. 2013 369 25 2391 2405Search in Google Scholar

10Fleischman AG, Tyner JW. Causal role for JAK2 V617F in thrombosis. Blood. 2013; 122(23): 3705-3706.FleischmanAGTynerJW. Causal role for JAK2 V617F in thrombosis Blood. 2013 122 23 3705 3706Search in Google Scholar

11Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014; 28(7): 1407-1413.TefferiAThieleJVannucchiAMBarbuiT. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms Leukemia. 2014 28 7 1407 1413Search in Google Scholar

12Peerschke EIB, Lopez JA. Platelet membranes and receptors. In: Loscalzo J, Schafer AI, Eds. Thrombosis and Hemorrhage, 2nd ed. Baltimore, MD, USA: Williams and Wilkins. 1998: 229-260.PeerschkeEIBLopezJA. Platelet membranes and receptors LoscalzoJSchaferAI Thrombosis and Hemorrhage 2nd Baltimore, MD, USA Williams and Wilkins 1998 229260Search in Google Scholar

13Andrews RK, Shen Y, Gardiner EE, Dong JF, Lopez JA, Berndt MC. The glycoprotein ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost. 1999; 82(2): 357-364.AndrewsRKShenYGardinerEEDongJFLopezJABerndtMC. The glycoprotein ib-IX-V complex in platelet adhesion and signaling Thromb Haemost. 1999 82 2 357 364Search in Google Scholar

14Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002; 8(11): 1227-1234.RuggeriZM. Platelets in atherothrombosis Nat Med. 2002 8 11 1227 1234Search in Google Scholar

15Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994; 31(3): 229-239.RuggeriZM. New insights into the mechanisms of platelet adhesion and aggregation Semin Hematol. 1994 31 3 229 239Search in Google Scholar

16Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, et al. Hemostatic gene poly-morphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis. 2004; 15(1): 21-24.Afshar-KharghanVLopezJAGrayLAPadillaABorthakurGRobertsSC Hemostatic gene poly-morphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia Blood Coagul Fibrinolysis. 2004 15 1 21 24Search in Google Scholar

17Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost. 2007; 5(7): 1403-1408.HoffmanMColinaCMMcDonaldAGArepallyGMPedersenLMonroeDM. Tissue factor around dermal vessels has bound factor VII in the absence of injury J Thromb Haemost. 2007 5 7 1403 1408Search in Google Scholar

18Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, et al. Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol. 2014; 93(2): 103-111.Buxhofer-AuschVOlcayduDGisslingerBSchallingMFrantalSThieleJ Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia Eur J Haematol. 2014 93 2 103 111Search in Google Scholar

19Bowen DJ, Collins PW. An amino acid polymorphism in von willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood. 2004; 103(3): 941-947.BowenDJCollinsPW. An amino acid polymorphism in von willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13 Blood. 2004 103 3 941 947Search in Google Scholar

20van ’t Hooft FM, Silveira A, Tornvall P, Iliadou A, Ehrenborg E, Eriksson P, et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood. 1999; 93(10): 3432-3441.van’t HooftFMSilveiraATornvallPIliadouAEhrenborgEErikssonP Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration Blood. 1999 93 10 3432 3441Search in Google Scholar

21Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, et al. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation. 2001; 104(13): 1459-1463.CroftSASamaniNJTeareMDHamptonKKSteedsRPChannerKS Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction Circulation. 2001 104 13 1459 1463Search in Google Scholar

22Pina-Cabral LB, Carvalhais V, Mesquita B, Escór-cio C, Salgado P, Santos A, et al. Allelic and genotypic frequencies of platelet glycoprotein polymorphisms in a portuguese population. Rev Port Cardiol. 2013; 32(2): 111-115.Pina-CabralLBCarvalhaisVMesquitaB Escór-cioCSalgadoPSantosA Allelic and genotypic frequencies of platelet glycoprotein polymorphisms in a portuguese population Rev Port Cardiol. 2013 32 2 111 115Search in Google Scholar

23Jimenez S, Tassies D, Espinosa G, Garcķa-Criado A, Plaza J, Monteagudo J, et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis. 2008; 67(6): 835-840.JimenezSTassiesDEspinosaG Garcķa-CriadoAPlazaJMonteagudoJ Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus Ann Rheum Dis. 2008 67 6 835 840Search in Google Scholar

24Yonal I, Hindilerden F, Hancer VS, Artim-Esen B, Daglar A, Akadam B, et al. The impact of platelet membrane glycoprotein ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome. Thromb Res. 2012; 129(4): 486-491.YonalIHindilerdenFHancerVS Artim-EsenBDaglarAAkadamB The impact of platelet membrane glycoprotein ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome Thromb Res. 2012 129 4 486 491Search in Google Scholar

25Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006; 367(9511): 651-658.YeZLiuEHHigginsJPKeavneyBDLoweGDCollinsR Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls Lancet. 2006 367 9511 651 658Search in Google Scholar

26Hoppe B, Tolou F, Dorner T, Kiesewetter H, Salama A. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: Frequency distribution in a healthy german population. Thromb Haemost. 2006; 96(4): 465-470.HoppeBTolouFDornerTKiesewetterHSalamaA. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: Frequency distribution in a healthy german population Thromb Haemost. 2006 96 4 465 470Search in Google Scholar

27Zhang LJ, Li HH, Tao SB, Yuan B, Yan HQ, Chang L, et al. FGB gene - 148C>T polymorphism is associated with increased risk of ischemic stroke in a Chinese population: A meta-analysis based on 18 case-control studies. Genet Test Mol Biomarkers. 2014; 18(6): 377-382.ZhangLJLiHHTaoSBYuanBYanHQChangL FGB gene - 148C>T polymorphism is associated with increased risk of ischemic stroke in a Chinese population: A meta-analysis based on 18 case-control studies Genet Test Mol Biomarkers. 2014 18 6 377 382Search in Google Scholar

28Zhang X, Li Y, Guo X, Du L, Ma J. Relationship between the -455G/A and -148C/T polymorphisms in the β-fibrinogen gene and cerebral infarction in the Xinjiang Uygur and Han Chinese populations. Neural Regen Res. 2012; 7(7): 546-551.ZhangXLiYGuoXDuLMaJ. Relationship between the -455G/A and -148C/T polymorphisms in the β-fibrinogen gene and cerebral infarction in the Xinjiang Uygur and Han Chinese populations Neural Regen Res. 2012 7 7 546 551Search in Google Scholar

29Liang L, Sun C, Xiao F, Tang XL, Chen XD, Zhou DF, et al. (See above) Nine polymorphisms of fibrinogen gene and their association with plasma fibrinogen levels in Hainan Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005; 22(4): 457-461.PAGELiangLSunCXiaoFTangXLChenXDZhouDF (See above) Nine polymorphisms of fibrinogen gene and their association with plasma fibrinogen levels in Hainan Han population Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 22 4 457 461Search in Google Scholar

30Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood. 2011; 117(22): 5857-5859.CarobbioAThieleJPassamontiFRumiERuggeriMRodeghieroF Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients Blood. 2011 117 22 5857 5859Search in Google Scholar

31Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120(26): 5182-5133.BarbuiTFinazziGCarobbioAThieleJPassamontiFRumiE Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis) Blood 2012 120 26 51825133Search in Google Scholar

32Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA. 1994; 91(4): 1396-1400.DahlbackBHildebrandB. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA. 1994 91 4 1396 1400Search in Google Scholar

33Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002; 71(1): 1-6.RuggeriMGisslingerHTosettoARintelenCMannhalterCPabingerI Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia Am J Hematol. 2002 71 1 1 6Search in Google Scholar

34Schwarz J, Ovesná P, Černá O, Kissová J, Maaloufová Soukupová J, Brychtová Y, et al.; CZEMP-Czech Group for Ph-Myeloproliferative Disorders. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. Eur J Haematol. 2016; 96(1): 98-106.SchwarzJOvesnáPČernáOKissováJMaaloufová SoukupováJBrychtováY CZEMP-Czech Group for Ph-Myeloproliferative Disorders. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide Eur J Haematol. 2016 96 1 98 106Search in Google Scholar

35De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009; 94(5): 733-737.De StefanoVZaTRossiEFioriniACiminelloALuzziC Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia Haematologica. 2009 94 5 733 737Search in Google Scholar

36Tevet M, Ionescu R, Dragan C, Lupu AR. Influence of the JAK2 V617F Mutation and inherited thrombophilia on the thrombotic risk among patients with myelo-roliferative disorders. Maedica (Buchar). 2015; 10(1): 27-32.TevetMIonescuRDraganCLupuAR. Influence of the JAK2 V617F Mutation and inherited thrombophilia on the thrombotic risk among patients with myelo-roliferative disorders Maedica (Buchar). 2015 10 1 27 32Search in Google Scholar